Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing: A Scientific Statement From the American Heart Association.

This article briefly reviews the challenges of cardio-oncology, the strengths and limitations of using human induced pluripotent stem cell-derived cardiomyocytes to represent clinical findings in the nonclinical research space, and future directions for their further use.
PMID: 31533542 [PubMed - as supplied by publisher]

Source: Circulation Research - September 18, 2019 Category: Cardiology Authors: Gintant G, Burridge P, Gepstein L, Harding S, Herron T, Hong C, Jalife J, Wu JC, American Heart Association Council on Basic Cardiovascular Sciences Tags: Circ Res Source Type: research